Merck & Co. (MRK) is Building a Stronger Future Beyond Its Keytruda Franchise

Merck & Co. (MRK) is Building a Stronger Future Beyond Its Keytruda Franchise

Thu, September 17, 2026 at 2:57 PM GMT+3 3 min read

• MRK +0.60%

Auxier Asset Management, an investment advisory firm, released its second-quarter 2026 investor letter. The letter can be downloaded here. Following a strong rebound from the first-quarter decline, the S&P 500 gained 15.2% as accelerating capital spending toward artificial intelligence infrastructure drove significant gains across technology hardware companies. Semiconductor and data-center-related businesses benefited from supply constraints and strong demand, while enterprise software remained under pressure as investors reassessed AI disruption risks and compressed valuations. In the quarter, Auxier Focus Fund's Investor Class gained 8.82% and 10.70% for the six months ended June 30, 2026. Despite strong earnings growth across the broader market, Auxier highlighted concerns around rising margin debt, increased leverage, and elevated capital flows into high-growth technology areas that could amplify future volatility. The firm continues to focus on identifying enduring businesses with strong competitive advantages, resilient cash flows, and sustainable long-term growth potential. Also, check the fund's top five holdings to see its best picks in 2026.

In its second-quarter 2026 investor letter, Auxier Asset Management highlighted Merck & Co., Inc. (NYSE:MRK). Merck & Co., Inc. (NYSE:MRK) is a leading healthcare company that offers human health pharmaceutical for various areas. On September 16, 2026, Merck & Co., Inc. (NYSE:MRK) closed at $144.91 per share. Over the past month, Merck & Co., Inc. (NYSE:MRK) declined 2.74% while its shares gained 77.74% over the past 52 weeks. Merck & Co., Inc. (NYSE:MRK) has a market capitalization of $357.52 billion with a 52-week trading range between $77.58 and $156.92.

Auxier Asset Management stated the following regarding Merck & Co., Inc. (NYSE:MRK) in its Q2 2026 investor letter:

"More clarity around federal drug pricing as well as faster FDA approvals were another tailwind for the pharmaceutical companies. AbbVie and Merck & Co., Inc. (NYSE:MRK) performed well on the back of record prescription volumes. Merck has been successfully executing with new products like Winrevair, Welireg, and Capvaxive reducing dependence on their cancer drug Keytruda which has long been the company's largest source of revenue."

Merck & Co., Inc. (NYSE:MRK) is not on our list of the 40 Most Popular Stocks Among Hedge Funds. As per our database, 101 hedge fund portfolios held Merck & Co., Inc. (NYSE:MRK) at the end of the second quarter which was 98 in the previous quarter. While we acknowledge the potential of Merck & Co., Inc. (NYSE:MRK) as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

In another article, we covered Merck & Co., Inc. (NYSE:MRK) and shared Jim Cramer's views on the company. In addition, please check out our hedge fund investor letters Q2 2026 page for more investor letters from hedge funds and other leading investors.

READ NEXT: 33 Stocks That Should Double in 3 Years and 15 Stocks That Will Make You Rich in 10 Years.

This article is originally published at Insider Monkey.